Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy
Roche in its second-quarter 2024 business report on Thursday unveiled plans to ramp up the development of its obesity candidates, which the pharma claims can differentiate them from an increasingly competitive weight-loss drug market. Roche Group CEO …